Immunovant, Inc. (IMVT)
NASDAQ: IMVT · IEX Real-Time Price · USD
32.52
+1.09 (3.47%)
At close: Mar 27, 2024, 4:00 PM
32.50
-0.02 (-0.06%)
Pre-market: Mar 28, 2024, 4:41 AM EDT

Immunovant Ratios and Metrics

Millions USD. Fiscal year is Apr - Mar.
Year Current2022202120202019
Market Capitalization
4,6572,0206411,571879
Market Cap Growth
-214.98%-59.19%78.83%-
Enterprise Value
3,9661,6451501,175778
PE Ratio
-25.03-9.58-4.09-14.63-13.24
PB Ratio
6.855.571.374.019.34
P/FCF Ratio
-28.95-10.72-6.03-18.81-16.46
P/OCF Ratio
-28.98-10.73-6.04-18.86-16.47
EV/EBITDA Ratio
-22.26-7.85-0.96-11.00-11.85
EV/EBIT Ratio
-22.14-7.80-0.96-10.90-11.85
EV/FCF Ratio
-25.67-8.73-1.41-14.06-14.58
Debt / Equity Ratio
0.000.000.010.01-
Debt / EBITDA Ratio
0.00-0.01-0.02-0.03-
Debt / FCF Ratio
0.00-0.01-0.02-0.04-
Quick Ratio
21.568.7111.3721.356.57
Current Ratio
22.149.3411.5221.797.12
Interest Coverage
-----105.07
Return on Equity (ROE)
-61.10%-52.40%-33.40%-28.40%-123.00%
Return on Assets (ROA)
-55.30%-48.30%-31.10%-27.00%-56.40%
Return on Capital (ROIC)
-39.15%-60.01%-33.04%-27.38%-70.24%
Earnings Yield
-5.23%-10.44%-24.44%-6.84%-7.56%
FCF Yield
-4.52%-9.33%-16.58%-5.32%-6.08%
Buyback Yield / Dilution
-12.40%-12.21%-24.98%-103.14%-94.85%
Total Shareholder Return
-12.40%-12.21%-24.98%-103.14%-94.85%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).